Wolfe Research lowered the firm’s price target on Silk Road Medical to $13 from $27 and keeps an Underperform rating on the shares. The new price target assumes a two multiple on the firm’s 2024 revenue forecast. The analyst’s estimate of the market conversion opportunity, or total U.S. carotid procedure volume, is 35%-40% below the company and Street.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SILK:
- DraftKings upgraded, Coinbase downgraded: Wall Street’s top analyst calls
- Silk Road Medical Tanks after CMS Decision on Stent Coverage Spooks Investors
- Silk Road Medical downgraded to Underperform from Buy at BofA
- Silk Road Medical downgraded to Neutral from Overweight at JPMorgan
- Citi sees CMS Medicare ruling as neutral for TCAR Procedures